Evidence Hub

Initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension: a case report

Park DH, Kamp JC, Seeliger B, Hoeper MM, Olsson KM

ERJ open research, 2026

Abstract

In this case report of a patient with newly diagnosed, severe idiopathic pulmonary arterial hypertension, near normalisation of haemodynamics was achieved with initial triple combination therapy including the activin signalling inhibitor sotatercept https://bit.ly/48RtbPT.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free